Publication
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerSkin Squamous Cell Carcinomacivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneHRAScivic_curation1.00
- variantHRAS G13Dcivic_curation1.00
Curated evidence
Evidence citing this paper (9)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22256804
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| HRAS G12D1 | ||||||||
| Vemurafenib | Skin Squamous Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID3698In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC | civic |
| HRAS G13D1 | ||||||||
| Vemurafenib | Skin Squamous Cell Carcinoma | Predictive | C | Supports Resistance | 1 | accepted | EID3851In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC | civic |
| HRAS G13V1 | ||||||||
| Vemurafenib | Skin Squamous Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID4418In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC | civic |
| HRAS Q61K1 | ||||||||
| Vemurafenib | Skin Squamous Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID3850In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC | civic |
| HRAS Q61L1 | ||||||||
| Vemurafenib | Skin Squamous Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID3848In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC | civic |
| HRAS Q61R1 | ||||||||
| Vemurafenib | Skin Squamous Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID3849In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC | civic |
| KRAS G12C1 | ||||||||
| Vemurafenib | Skin Squamous Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID3982In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC | civic |
| KRAS G12D1 | ||||||||
| Vemurafenib | Skin Squamous Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID3961In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC | civic |
| TP53 P278S1 | ||||||||
| Vemurafenib | Skin Squamous Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID4419In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC | civic |